Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
about
Smoldering multiple myelomaSmoldering multiple myeloma requiring treatment: time for a new definition?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementRecent advances in multiple myeloma: a Korean perspectiveSmoldering multiple myeloma.Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.How I treat smoldering multiple myeloma.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trialsPositron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.Myeloma today: Disease definitions and treatment advances.The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaPotential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaQuantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.The Evolution of Prognostic Factors in Multiple Myeloma.New approaches to smoldering myeloma.Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Management of asymptomatic myeloma patients.The road to cure in multiple myeloma starts with smoldering disease.V. Smoldering multiple myeloma.Performance Evaluation of Serum Free Light Chain Analysis: Nephelometry vs Turbidimetry, Monoclonal vs Polyclonal Reagents.Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.Diagnostic Advances in Multiple Myeloma.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodRole of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agentsHaematological cancer: Treatment of smoldering multiple myeloma.A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
P2860
Q26863331-56BAAB65-6B3C-4579-B235-55A176904953Q26996579-1D9DE994-4695-49A5-9C65-82384032790AQ26998884-006CEE9B-CC5E-4C8C-8A7F-6718449C2706Q28074521-13063682-63C3-4C0D-A401-DCBE87963297Q28082855-9E72A90A-1178-4233-ADC5-DAFE8ABD4A34Q34455098-760E610E-E458-4410-97DA-734D3D1B1A47Q34525834-4C81232B-0F9E-4EDB-BD85-583A8ECDCEEDQ34557651-83300F1F-D50B-4727-AF99-6558171DC06EQ34580094-5C09BAF0-AD76-4405-9DF3-AF25A5DA90C6Q35244883-5D38427C-BD86-4A2E-BC33-84051BBFD7A7Q35298727-566DA3AC-48CE-4E2C-A3A8-E7BC20A8B6DAQ36254248-37E35547-590C-49BF-BE4B-2F69132E7602Q36470699-A0628784-BF63-4047-864C-F9503A14DB7AQ36673465-6B02BE1C-2B8D-4FCA-AA02-5170717D9D8FQ36708969-926FC175-6A38-4F12-B942-4DB04B4C85AFQ37171994-1848BBF0-E348-455E-AFD2-886299C11A5DQ37327618-3173F652-B18E-4BCD-BCF2-3D659E16B637Q37429722-009FFCEC-CD1F-4B44-8F31-369FE904BECFQ37528072-FCD4A807-2943-4BA5-A88D-05F35B16BBDEQ37593481-7EA7F316-13BA-406C-BEA6-02F9874106B5Q37683483-FA81A1C4-0D48-4074-BC69-3D64A0ED1DFDQ38131457-6A5C3EF4-407D-4AC1-950B-62A1F104C920Q38165722-8166FF46-4021-48D8-A23B-E150D4ED47C7Q38168869-695B32EA-C6AB-46C3-BE9B-2447FA66808FQ38190593-14868983-5C4B-4358-B778-479ADCF4D648Q38255333-922B69D5-4CEE-4D27-99BC-E2DACFA0E453Q38264322-204AEAD6-1068-4A94-AAF1-D92A1B1257EBQ38494968-3B416EB6-BE87-459A-9866-AFC2947E79CCQ38523976-A292D725-FDFB-4E66-BE9F-74D5977A2FCAQ38675621-8A18E0D4-FB96-4E26-A583-E2CD02BD24C3Q38740697-8868A1ED-C8C4-42F6-94EE-4C67DF68FBBCQ38753310-CD26500C-6452-43E6-9462-EE800436DB73Q38911216-CF06D59A-E198-4BE2-B74A-5051AA71C869Q38970567-CBEA00B7-E172-4AFF-A716-882FD6A00AD3Q40165182-90B89E2C-C252-4F3B-9D9E-AF541FBD4D51Q40404841-1817B6BA-C216-4D62-B5C1-572F879F4B22Q41557109-F23C6BB3-7E1D-4397-BBCB-718FB91079E4Q42361980-ED9160B1-A835-4F77-9C82-6CF3E887D93BQ45965429-114C4A42-F6EC-48B8-9848-DCBC7CCEBF57Q46440869-D610F949-D642-4A4A-A76C-D42DE66D1E62
P2860
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@ast
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@en
type
label
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@ast
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@en
prefLabel
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@ast
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
@en
P2093
A Dispenzieri
J A Katzmann
J T Larsen
P2860
P2888
P304
P356
10.1038/LEU.2012.296
P577
2012-10-16T00:00:00Z
P5875
P6179
1043026814